DaVita Shifts Its Business Model With HealthCare Partners Acquisition
This article was originally published in The Pink Sheet Daily
Dialysis provider DaVita acquires one of the largest independent physician associations, HealthCare Partners, for $4.4 billion in cash and stock, as well as earn-outs.
You may also be interested in...
With FDA’s March 27 approval of peginesatide to prevent anemia in CKD patients on dialysis, Affymax will focus initially on marketing to smaller, price-conscious dialysis providers. But the biotech also expects to do business with Fresenius and, to a lesser degree, Davita.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.